UK Clinical Trials Show Signs of Recovery After Years of Decline

New data from the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a resurgence in clinical trial activity in the country, marking a significant turnaround after years of decline. The report highlights a 9% increase in applications to commence studies between January and November 2024 compared to the same period in 2023, with the most substantial growth seen in early-stage trials. This uptick has been described as an “encouraging sign” by the Association of the British Pharmaceutical Industry (ABPI).

The MHRA’s findings, presented during the JP Morgan Healthcare Conference in San Francisco, reveal a 16% increase in studies involving healthy volunteers and a 5% rise in first-in-human studies. Notably, there was a 7% increase in trials being conducted in the UK for the first time, which signals growing international confidence in the UK as a favorable location for launching new research initiatives.

Perhaps the most striking data point is the 75% increase in requests from company sponsors for advisory meetings with the MHRA. These meetings aim to ensure that study protocols are correctly designed from the outset, thereby reducing the likelihood of costly delays later in the process. “These impressive gains have been made within the limitations of the current regulatory framework,” stated Lawrence Tallon, chief executive of the MHRA. He added that a comprehensive package of reforms is set to take effect in April, which will further enhance the clinical trials landscape.

Planned Reforms to Streamline Clinical Trials

The upcoming changes include the introduction of a fast-track notification route to expedite the initiation of studies, allowing patients to access new treatments more quickly. The MHRA anticipates that approximately 20% of studies will utilize this fast-track option, which aims to eliminate some of the bureaucratic hurdles associated with lower-risk studies. This will also help to allocate more resources toward evaluating more complex trials.

In addition to the fast-track route, the MHRA will implement a 14-day assessment pathway for phase 1 trials, restoring a rapid route for first-in-human testing of new medicines. The agency also plans to consider safety data from international studies and will introduce systems to assess computer simulations, known as in silico trials, which can predict how new medicines may behave prior to patient testing.

“Clinical trial sponsors are clear about what they need: speed, clarity, and flexibility,” Tallon said. The new regulations are designed to simplify the initiation of lower-risk studies, bolster support for early-stage research, and embrace modern methodologies, including adaptive trial designs and computer model simulations, all while prioritizing patient safety.

Addressing Historical Declines in Clinical Research

The revitalization of the clinical trials sector is particularly significant given the alarming trends observed in previous years. A report from the ABPI indicated a 41% decline in new trial initiations between 2017 and 2021. Additionally, a report by Lord O’Shaughnessy highlighted that the UK was losing ground to other nations as a hub for clinical research, prompting a series of recommendations aimed at reversing this trend. Many of these recommendations are now being implemented by the MHRA.

Recent figures from the NHS’s Health Research Authority showed a 17% increase in overall trial participation, with more than 450,000 individuals taking part in trials in the 2024/25 period compared to the previous year. However, participation in commercial trials has seen a decline of around 25%, with commercial studies comprising just over 3% of the total number of international studies conducted. The ABPI’s analysis indicates that patient recruitment for trials in 2024/25 is at its lowest level since 2017/18.

In a statement, Dr. Janet Valentine, head of innovation and research policy at the ABPI, emphasized the importance of speed and predictability in regulatory approvals. “These factors are critical to setting up clinical trials and will be essential to meeting the government’s ambition of a 150-day set-up time,” she said. The MHRA’s efforts to accelerate regulatory processes are welcomed, but sustaining these improvements will be vital for the UK to consistently achieve rapid trial initiation and effective patient recruitment.